-
公开(公告)号：EP4055050A2
公开(公告)日：2022-09-14
申请号：EP20816095.2
申请日：2020-11-06
发明人： ANLAHR, Jonas , ARVEDSON, Tara , BAILIS, Julie , CHUN, Matthew , D'ANGELO, Igor , DAHLHOFF, Christoph , EVERTS, Stephanie , FRIEDRICH, Matthias , GAEDTKE, Lars , HOFFMANN, Patrick , GOLDSTEIN, Rebecca , HONER, Jonas Karl-Josef , KISCHEL, Roman , KLINGER, Matthias , KUFER, Peter , MUENZ, Markus , NAEGELE, Virginie , PANZER, Marc , RAU, Doris , RAUM, Tobias , ULLRICH, Ines
-
公开(公告)号：EP3611193A1
公开(公告)日：2020-02-19
申请号：EP19196304.0
申请日：2012-11-15
发明人： KUFER, Peter , RAUM, Tobias , HOFFMANN, Patrick , KISCHEL, Roman , LUTTERBUESE, Ralf , RAU, Doris , ADAM, Paul , BORGES, Eric , HEBEIS, Barbara , HIPP, Susanne
IPC分类号： C07K16/28 , A61K39/395 , A61P35/02 , A61P37/00
摘要： The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster 3 of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.
-
公开(公告)号：EP2780374B1
公开(公告)日：2019-08-21
申请号：EP12803509.4
申请日：2012-11-15
发明人： KUFER, Peter , RAUM, Tobias , HOFFMANN, Patrick , KISCHEL, Roman , LUTTERBUESE, Ralf , RAU, Doris , ADAM, Paul , BORGES, Eric , HEBEIS, Barbara , HIPP, Susanne
IPC分类号： C07K16/28 , A61K39/395 , A61P35/02 , A61P37/00
-
4.发明公开RISK-STRATIFICATION OF B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS 审中-公开肌酸激酶诱导麻醉剂阿司匹林LYMPHATISCHER B-VORLÄUFER-LEUKÄMIE
公开(公告)号：EP3149480A1
公开(公告)日：2017-04-05
申请号：EP15727072.9
申请日：2015-05-20
发明人： ZUGMAIER, Gerhard , KUFER, Peter , ALEKAR, Shilpa
IPC分类号： G01N33/574
CPC分类号： G01N33/57426 , A61K35/17 , A61K38/1774 , A61K2035/124 , C07K16/2803 , C07K16/2809 , C07K2317/31 , C07K2317/622 , G01N33/5091 , G01N2333/70503 , G01N2800/50 , G01N2800/52 , G01N2800/56
摘要： The present invention relates to a method for risk-stratifying subjects suffering from B-precursor acute lymphoblastic leukemia (ALL), wherein said subjects are intended for a therapy comprising administration of a CD3 binding domain. Risk-stratification is based on the determination of the amount blast cells in a bone marrow sample from said subject, and/or on the determination of the number of blast cells per 1 μl in a CSF sample from said subject. According to the category into which subjects are risk-stratified, said subjects can be appropriately treated, while their risk of a potential adverse neurological reaction can be reduced or even excluded.
摘要翻译： 本发明涉及一种用于风险分层患有B-前体急性淋巴细胞性白血病（ALL）的受试者的方法，其中所述受试者旨在用于包括施用CD3结合结构域的治疗。 风险分层是基于来自所述受试者的骨髓样品中的胚细胞数量的确定和/或来自所述受试者的CSF样品中每1μl的胚细胞数量的确定。 根据受试者风险分层的类别，可以对所述受试者进行适当的治疗，同时可以降低甚至排除潜在的不利神经反应的风险。
-
公开(公告)号：EP4240768A2
公开(公告)日：2023-09-13
申请号：EP21815915.0
申请日：2021-11-08
发明人： EVERTS, Stephanie , KLINGER, Matthias , NAEGELE, Virginie , ZALEWSKI, Adam , BLUEMEL, Claudia , BOEHM, Thomas , BROZY, Johannes , D'ANGELO, Igor , KUFER, Peter , LUTTERBUESE, Petra , MUENZ, Markus , RAU, Doris , RAUM, Tobias , RATTEL, Benno , THOMAS, Oliver , ULLRICH, Ines , WAHL, Joachim , WEBHOFER, Christian , WEIDLER, Sascha , PHAM, Elizabeth , BAILIS, Julie
IPC分类号： C07K16/28 , C07K16/30 , A61K39/395
-
公开(公告)号：EP4039709A1
公开(公告)日：2022-08-10
申请号：EP21214955.3
申请日：2017-02-02
发明人： RAUM, Tobias , MUENZ, Markus , BROZY, Johannes , KUFER, Peter , HOFFMANN, Patrick , FRIEDRICH, Matthias , RATTEL, Benno , BOGNER, Pamela , WOLF, Andreas , POMPE, Cornelius
摘要： The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3ε chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
-
公开(公告)号：EP2780375B1
公开(公告)日：2019-09-11
申请号：EP12805432.7
申请日：2012-11-15
发明人： KUFER, Peter , RAUM, Tobias , HOFFMANN, Patrick , KISCHEL, Roman , LUTTERBUESE, Ralf , RAU, Doris , ADAM, Paul , BORGES, Eric , HEBEIS, Barbara , HIPP, Susanne
IPC分类号： C07K16/28 , A61K39/395 , A61P35/02 , A61P37/00
-
公开(公告)号：EP3149480B1
公开(公告)日：2018-12-26
申请号：EP15727072.9
申请日：2015-05-20
发明人： ZUGMAIER, Gerhard , KUFER, Peter , ALEKAR, Shilpa
IPC分类号： G01N33/574
CPC分类号： G01N33/57426 , A61K35/17 , A61K38/1774 , A61K2035/124 , C07K16/2803 , C07K16/2809 , C07K2317/31 , C07K2317/622 , G01N33/5091 , G01N2333/70503 , G01N2800/50 , G01N2800/52 , G01N2800/56
摘要： The present invention relates to a method for risk-stratifying subjects suffering from B-precursor acute lymphoblastic leukemia (ALL), wherein said subjects are intended for a therapy comprising administration of a CD3 binding domain. Risk-stratification is based on the determination of the amount blast cells in a bone marrow sample from said subject, and/or on the determination of the number of blast cells per 1 μl in a CSF sample from said subject. According to the category into which subjects are risk-stratified, said subjects can be appropriately treated, while their risk of a potential adverse neurological reaction can be reduced or even excluded.
-
公开(公告)号：EP3411402A1
公开(公告)日：2018-12-12
申请号：EP17703376.8
申请日：2017-02-02
发明人： RAUM, Tobias , MUENZ, Markus , BROZY, Johannes , KUFER, Peter , HOFFMANN, Patrick , FRIEDRICH, Matthias , RATTEL, Benno , BOGNER, Pamela , WOLF, Andreas , POMPE, Cornelius
IPC分类号： C07K16/28
CPC分类号： C07K16/2878 , A61K2039/505 , C07K16/2809 , C07K2317/31 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/56 , C07K2317/622 , C07K2317/64 , C07K2317/94 , C07K2319/00
摘要： The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3ε chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
-
公开(公告)号：EP2948477A1
公开(公告)日：2015-12-02
申请号：EP14705293.0
申请日：2014-01-27
发明人： XIAO, Shouhua , PAN, Zheng , WICKRAMASINGHE, Dineli , JEFFRIES, M., Shawn , KING, Chadwick Terence , CHAN, Brian Mingtung , KUFER, Peter , LUTTERBUESE, Ralf , RAUM, Tobias , HOFFMANN, Patrick , RAU, Doris , KISCHEL, Roman , LEMON, Bryan , WESCHE, Holger
CPC分类号： C07K16/2809 , A61K47/60 , A61K2039/505 , C07K16/28 , C07K16/2896 , C07K16/3053 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/565 , C07K2317/569 , C07K2317/622 , C07K2317/626 , C07K2317/73 , C07K2317/77 , C07K2317/92 , C07K2319/00
摘要： The present invention provides to a antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention relates to a nucleic acid sequence encoding the antibody construct, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention relates a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
摘要翻译： 本发明提供一种抗体构建物，其包含能够结合靶细胞表面上的人CDH19的第一人结合结构域和能够结合T细胞表面上的人CD3的第二结构域。 此外，本发明涉及编码抗体构建体的核酸序列，包含所述核酸序列的载体和用所述载体转化或转染的宿主细胞。 此外，本发明涉及制备本发明的抗体构建体的方法，所述抗体构建体的医学用途和包含所述抗体构建体的试剂盒。
-
-
-
-
-
-
-
-
-
搜索结果
63 条记录 (耗时 0.032 秒)
